Longeveron Inc. (LGVN), a clinical-stage biotechnology company, released its full-year 2025 financial results and provided a business update. The company reported revenues of $1.2 million, alongside progress in its stem cell therapy pipeline led by laromestrocel.
Financial Highlights
Revenues for 2025 totaled $1.2 million, comprising $1.0 million from clinical trials and $0.2 million from contract manufacturing. This marks a 50% decline from $2.4 million in 2024, primarily due to reduced demand in clinical trials and manufacturing.
General and administrative expenses rose 17% to $12 million from $10.3 million, driven by increased personnel costs and a one-time CEO severance payment. Research and development expenses increased 48% to $12 million from $8.1 million, reflecting higher personnel and equity compensation ($2.2 million), CMC activities for biologics license application readiness ($1.4 million), and patent amortization ($0.2 million).
The net loss widened to $22.7 million in 2025, up 41% from $16 million the prior year. As of December 31, 2025, Longeveron held $4.7 million in cash and $1.4 million in working capital. On March 11, 2026, the company closed a $15.9 million tranche of a private placement led by Coastlands Capital and Janus Henderson Investors, with potential for an additional $15 million upon milestones. This extends the cash runway into Q4 2026.
60
59
Pipeline Progress: HLHS Program Leads
Stephen Willard, Chief Executive Officer, highlighted the company’s strong position in stem cell science. “With a strong foundation in stem cell science and multiple positive clinical trials with our stem cell therapy across several indications, Longeveron is well positioned,” Willard stated.
The Hypoplastic Left Heart Syndrome (HLHS) program remains the top priority. Enrollment in the pivotal Phase 2b ELPIS II trial concluded in June 2025 with 40 patients. Top-line results are expected in Q3 2026. FDA feedback indicates the trial could support a Biologics License Application (BLA) submission in 2027 if efficacy is demonstrated. Laromestrocel targets improved cardiac function in HLHS infants, a rare pediatric disease eligible for a Priority Review Voucher (PRV), with recent PRVs sold for $150 million to $205 million. Investors receive 50% of any PRV proceeds.
Nataliya Agafonova, Chief Medical Officer, confirmed the program advances toward a near-term approval pathway. Joshua Hare, Co-Founder, Chief Science Officer, and Executive Chairman, emphasized the potential of stem cell therapies for unmet needs, citing publications in Nature Medicine and Cell Stem Cell.
Pediatric Dilated Cardiomyopathy (PDCM) Advances
The IND for PDCM became effective in July 2025. Longeveron plans a single pivotal Phase 2 registrational study in 2027, following 2026 planning. The trial targets 70 patients with quarterly dosing over one year, using a hierarchical composite endpoint to reduce transplants and hospitalizations. PDCM also qualifies for a PRV, fully owned by the company. Agafonova noted the high unmet need, with 40% of affected children facing transplant or death within two years.
Strategic Initiatives
Longeveron pursues partnerships across programs, including HLHS post-ELPIS II, Alzheimer’s disease leveraging Phase 2 data, and PDCM. Willard stated, “We plan to focus on a robust partnering strategy across our development programs.” Manufacturing scales via a CDMO partnership. A recent patent covers laromestrocel for female sexual dysfunction, viewed as a partnership opportunity.
Analyst Q&A Insights
Raghuram Selvaraju of H.C. Wainwright inquired about PRVs and manufacturing. Willard confirmed PDCM PRV eligibility and CMC progress. On non-dilutive funding for Alzheimer’s and frailty, partnerships are prioritized, with interest from a recent Cell Stem Cell publication.
Boobalan Pachaiyappan of Roth Capital asked about BLA timelines. Hare noted eligibility for rolling submission and priority review. Agafonova outlined a potential 2027 BLA if data supports. On PDCM, details aligned with trial plans. PRV sales remain attractive despite the 2029 sunset.
